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A corrigendum on
Cancer cell gene expression modulated from plasma membrane integrin αvβ3 by thyroid
hormone and nanoparticulate tetrac
by Davis PJ, Glinsky GV, Lin H-Y, Leith JT, Hercbergs A, Tang H-Y, et al. Front Endocrinol (2015)
5:240. doi: 10.3389/fendo.2014.00240
In Table 2, the section designated “Disabling of cell survival pathway gene expression,” line 5
incorrectly states “: : :pro-apoptotic miR-21”; the correct statement is “: : :pro-apoptotic miR-15A.”
The issue is correctly discussed in the body of the published text, p. 2, right column, paragraph 4.
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